Can you provide the average price target for ORGANON & CO stock?
16 analysts have analysed OGN and the average price target is 9.18 USD. This implies a price increase of 44.57% is expected in the next year compared to the current price of 6.35.
NYSE:OGN • US68622V1061
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for ORGANON & CO (OGN).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-02-24 | Barclays | Maintains | Underweight -> Underweight |
| 2025-12-09 | Barclays | Initiate | Underweight |
| 2025-11-11 | JP Morgan | Maintains | Underweight -> Underweight |
| 2025-11-11 | Morgan Stanley | Maintains | Equal-Weight -> Equal-Weight |
| 2025-05-15 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2025-05-05 | Morgan Stanley | Maintains | Equal-Weight -> Equal-Weight |
| 2025-04-09 | Morgan Stanley | Maintains | Equal-Weight -> Equal-Weight |
| 2025-02-14 | Barclays | Maintains | Overweight -> Overweight |
| 2025-02-14 | Morgan Stanley | Maintains | Equal-Weight -> Equal-Weight |
| 2024-09-06 | JP Morgan | Downgrade | Neutral -> Underweight |
| 2024-05-06 | Goldman Sachs | Maintains | Neutral -> Neutral |
| 2024-05-03 | Goldman Sachs | Maintains | Neutral -> Neutral |
| 2024-04-29 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2024-02-20 | Goldman Sachs | Maintains | Neutral -> Neutral |
| 2023-11-22 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2023-11-03 | Goldman Sachs | Downgrade | Buy -> Neutral |
| 2023-10-25 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2023-10-11 | Morgan Stanley | Maintains | Equal-Weight -> Equal-Weight |
| 2023-09-21 | Barclays | Initiate | Overweight |
| 2023-08-09 | Morgan Stanley | Maintains | Equal-Weight -> Equal-Weight |
| 2023-05-08 | Morgan Stanley | Maintains | Equal-Weight |
| 2023-03-16 | Raymond James | Initiate | Outperform |
| 2022-11-04 | Morgan Stanley | Maintains | Equal-Weight |
| 2022-10-14 | B of A Securities | Downgrade | Neutral -> Underperform |
| 2022-10-12 | Morgan Stanley | Maintains | Equal-Weight |
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 6.263B 1.44% | 6.403B 2.24% | 6.216B -2.92% | 6.242B 0.42% | 6.346B 1.67% | 6.414B 1.07% | 6.525B 1.73% | 6.57B 0.69% | 6.52B -0.76% | 6.373B -2.25% | |
| EBITDA YoY % growth | 1.548B -20.70% | 1.742B 12.53% | 1.706B -2.07% | 1.927B 12.95% | 1.992B 3.37% | 2.076B 4.22% | 2.365B 13.92% | 2.416B 2.16% | 2.348B -2.81% | 2.302B -1.96% | |
| EBIT YoY % growth | 1.312B -24.60% | 1.465B 11.66% | 1.345B -8.19% | 1.694B 25.95% | 1.774B 4.72% | 1.85B 4.28% | 1.92B 3.78% | 1.95B 1.56% | 1.862B -4.51% | 1.796B -3.54% | |
| Operating Margin | 20.95% | 22.88% | 21.64% | 27.14% | 27.95% | 28.84% | 29.43% | 29.68% | 28.56% | 28.18% | |
| EPS YoY % growth | 4.14 -17.69% | 4.11 -0.72% | 3.66 -10.95% | 3.50 -4.34% | 3.76 7.29% | 4.21 12.18% | 3.84 -8.92% | 3.94 2.63% | 3.74 -5.13% | 3.59 -4.05% |
All data in USD
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|
| EPS Q2Q % growth | 0.84 -17.90% | 0.94 -5.95% | 1.04 2.97% | 0.88 39.48% |
| Revenue Q2Q % growth | 1.513B | 1.592B -0.13% | 1.558B -2.75% | 1.537B 1.99% |
| EBITDA Q2Q % growth | 445.41M 9.17% | 498.27M -6.69% | N/A | N/A |
| EBIT Q2Q % growth | 432.28M 33.42% | 462.58M 28.14% | 453.49M 16.88% | 431.37M 52.43% |
All data in USD
16 analysts have analysed OGN and the average price target is 9.18 USD. This implies a price increase of 44.57% is expected in the next year compared to the current price of 6.35.
ORGANON & CO (OGN) will report earnings on 2026-04-29.
The consensus EPS estimate for the next earnings of ORGANON & CO (OGN) is 0.84 USD and the consensus revenue estimate is 1.51B USD.
The number of analysts covering ORGANON & CO (OGN) is 16.